We recommend pembrolizumab with platinum-based chemotherapy as the most appropriate first-line ICI regimen for advanced NSCLC and suggest the combined use of PD-L1 expression and TMB to evaluate patients’ survivals and responses to precision immunotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.